Sphera Funds Management LTD. lifted its position in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 100.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,000 shares of the biopharmaceutical company’s stock after purchasing an additional 15,000 shares during the quarter. Sphera Funds Management LTD. owned 0.12% of Intercept Pharmaceuticals worth $3,632,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of ICPT. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intercept Pharmaceuticals by 14.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 132 shares during the period. US Bancorp DE acquired a new position in shares of Intercept Pharmaceuticals during the first quarter worth approximately $130,000. IFP Advisors Inc raised its position in shares of Intercept Pharmaceuticals by 128.1% during the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 730 shares during the period. Quantbot Technologies LP acquired a new position in shares of Intercept Pharmaceuticals during the first quarter worth approximately $170,000. Finally, Pacer Advisors Inc. raised its position in shares of Intercept Pharmaceuticals by 21.6% during the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 330 shares during the period. 82.19% of the stock is currently owned by institutional investors.
In other Intercept Pharmaceuticals news, Director Daniel G. Welch sold 217 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total transaction of $27,506.92. Following the sale, the director now directly owns 3,710 shares in the company, valued at $470,279.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Mark Pruzanski sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $130.80, for a total value of $5,232,000.00. Following the sale, the chief executive officer now owns 611,718 shares in the company, valued at $80,012,714.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,013 shares of company stock valued at $6,198,747. 9.20% of the stock is owned by corporate insiders.
Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at 94.88 on Friday. The stock’s 50 day moving average price is $108.47 and its 200 day moving average price is $116.36. The company’s market cap is $2.38 billion. Intercept Pharmaceuticals, Inc. has a 1-year low of $85.88 and a 1-year high of $172.95.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($3.14) earnings per share. On average, equities analysts anticipate that Intercept Pharmaceuticals, Inc. will post ($14.06) earnings per share for the current fiscal year.
ICPT has been the topic of a number of research reports. Laidlaw reaffirmed a “hold” rating and set a $119.00 target price (up from $115.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 1st. Cowen and Company reissued an “outperform” rating and issued a $232.00 price target on shares of Intercept Pharmaceuticals in a research report on Thursday. BMO Capital Markets increased their price target on Intercept Pharmaceuticals from $218.00 to $221.00 and gave the company an “outperform” rating in a research report on Tuesday, August 1st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Finally, Cantor Fitzgerald reissued an “underweight” rating and issued a $69.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $207.75.
TRADEMARK VIOLATION WARNING: This article was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2017/09/17/sphera-funds-management-ltd-buys-15000-shares-of-intercept-pharmaceuticals-inc-icpt.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.